These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24308155)

  • 1. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
    Zhang H; Tian M; Xiu C; Wang Y; Tang G
    Oncol Res; 2013; 20(10):447-55. PubMed ID: 24308155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
    Hahn T; Alvarez I; Kobie JJ; Ramanathapuram L; Dial S; Fulton A; Besselsen D; Walker E; Akporiaye ET
    Int J Cancer; 2006 May; 118(9):2220-31. PubMed ID: 16331615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X; Lu C; Xiao B; Qiao J; Sun Y
    J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
    Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
    BMC Cancer; 2010 Aug; 10():464. PubMed ID: 20804550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
    Xu M; Yao Y; Hua W; Wu Z; Zhong P; Mao Y; Zhou L; Luo F; Chu Y
    J Neurooncol; 2014 Feb; 116(3):497-504. PubMed ID: 24398615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
    Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
    Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
    Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
    Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
    Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based immunotherapy of malignant gliomas.
    Parajuli P; Sloan AE
    Cancer Invest; 2004; 22(3):405-16. PubMed ID: 15493362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
    Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
    Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
    Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
    Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].
    Liu JP; Wei HB; Zheng ZH; Guo WP; Fang JF
    Yao Xue Xue Bao; 2009 Dec; 44(12):1353-8. PubMed ID: 21351468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
    Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
    J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
    Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
    Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
    Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.